| Outcome Measures: |
Primary: Change value of glycosylated hemoglobin (HbA1c), Change value of HbA1c from baseline following 26 weeks of therapy, Baseline and 26 weeks | Secondary: Percentage of patients achieving HbA1c ≤7% or HbA1c ≤6.5%, Percentage of patients in each arm achieving HbA1c ≤7% or HbA1c ≤6.5% after 26 weeks of treatment., Baseline, week 26|Change value of HbA1c, Change value of HbA1c from baseline following 14 weeks of therapy, Baseline, week 14|Change value of fasting blood glucose, Change value of fasting blood glucose following 14 and 26 weeks of therapy, Baseline, week 14, week 26|Adverse events (AEs) and serious adverse events (SAEs), AEs and SAEs and their incidence during the 26-week treatment period, and then determine the correlation with the drug, Baseline to week 26|Hypoglycemia, Frequency of severe or symptomatic hypoglycemia during the 26-week treatment period, Baseline to week 26|Immunogenicity, The occurrence of immunogenicity during the 26-week treatment period by detecting Anti-Drug-Antibody(ADA)., Baseline, week 14, week 26|Abnormal findings, Abnormal findings during the 26-week treatment period，including abnormal findings of blood routine test，blood biochemical test as well as other abnormal laboratory findings., Baseline to week 26
|
| Locations: |
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, 400010, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China
|
